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Abstract
Background: Clostridium difficile is a leading infectious cause of health care associated diarrhoea. Several industrialised
countries have reported increased C. difficile infections and outbreaks, which have been attributed to the emergent PCR
ribotype 027 strain.
Methods and Findings: We conducted a case-case study to compare severity of C. difficile disease for patients with 027
versus non-027 ribotypes. We retrospectively collected clinical information about 123/136 patients with C. difficile infections
admitted to hospitals in the East of England region in 2006 and from whom stool isolates were cultured and ribotyped as
part of an earlier national survey. We defined severe C. difficile disease as having one or more of shock, paralytic ileus,
pseudo membranous colitis or toxic megacolon. Patient median age was 83 years old (range 3 to 98, interquartile range 75
to 89), 86% were prescribed antibiotics in the eight weeks before illness onset, 41% had ribotype 027 and 30-day all cause
mortality during hospital admission was 21%. Severe disease occurred in 24% (95%CI 13% to 37%) and 17% (95%CI 9% to
27%) of patients with PCR ribotype 027 and non-027 ribotypes respectively. In a multivariable model, ribotype 027 was not
associated with severe disease after adjusting for sex, discharge from hospital prior to 60 days of current admission,
gastroenteritis on admission, number of initiator antibiotics for C. difficile disease, and hospital where the patient was
admitted.
Conclusions: Our study found no evidence to support previous assertions that ribotype 027 is more virulent than other PCR
ribotypes. This finding raises questions about the contribution of this strain to the recent increase in C. difficile disease
throughout North America and Europe.
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Introduction
Clostridium difficile is a Gram-positive spore forming anaerobic
bacterium that is found in the normal gut flora of man. Clostridium
difficile associated disease (CDAD) generally follows ingestion of
antibiotics that leads to selection of toxin-producing strains,
resulting in a leading infectious cause of health care associated
diarrhoea [1]. CDAD ranges from mild uncomplicated diarrhoea
to severe diarrhoea complicated by one or more of fluid loss,
shock, leukocytosis, paralytic ileus, pseudomembranous colitis, and
toxic megacolon, and sometimes death [2]. Prevention and control
of CDAD crucially depends on maintaining high levels of
institutional hygiene, including the prompt recognition and
isolation of individuals with application of enteric precautions,
and on minimising exposure to antibiotics [1].
Molecular typing of toxigenic strains of C. difficile based on
detection of genes encoding toxins A and B within the pathogenicity
locus (PaLoc) [3,4] has led to the recognition of at least 22 distinct
toxinotypes [3,5]. Health systems in a number of industrialised
countries have reported recent increases of C. difficile infections and
outbreaks have been attributed to the emergence of a strain
characterised as toxinotype III, North American pulsed-field type 1,
PCRribotype 027[6,7,8,9,10].Ithasbeen asserted thatthisstrainis
more virulent than other strains [3,11], a notion supported by very
high levels of toxin A and B production in vitro [11]. It is possible,
however, that the impression of greater virulence of the 027
ribotype could reflect, at least in part, biases in the sampling, testing
and reporting of cases. In this study, we examine whether patients
with CDAD due to ribotype 027 had more severe disease than
patients with CDAD caused by other ribotypes.
Methods
Study Design
We conducted a case-case study. This study design is a variant
of the case-control design whereby only cases with the disease (in
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grouped by subtype of infectious disease organism, in this case C.
difficile 027 versus non-027 ribotypes, and their outcomes (here we
consider clinical severity of disease) are compared. The advantage
of using a case-case design is that it frequency matches on all
aetiological factors, both known and unknown, and selects groups
that are similar for disease-specific risk factors [13]. In this study, a
case-case design provides a non-biased comparison of disease
severity among patients with different strains of C. difficile.
Identification of Patients
We retrospectively identified inpatient cases of C. difficile from
16 National Health Service (NHS) hospitals in the East of England
region included in a national survey of C. difficile PCR ribotypes, as
reported elsewhere [14,15]. The survey selected all patients with
CDAD detected by microbiology laboratories in the East of
England during one allocated week between 9 January and 3
March 2006. Stool isolates from these patients were sent to the
regional coordinating laboratory where anaerobic culture was
undertaken. PCR ribotyping was done by the Health Protection
Agency Anaerobe Reference Laboratory in Cardiff.
Data Collection
We developed a structured proforma to extract information from
medicalrecordsaboutpatients’demographicdetails;maindiagnosis
at admission; treatment during 8 weeks prior to diagnosis of
suspected CDAD with antibiotics, H2 agonists and proton-pump
inhibitors; C. difficile-related illness; and all cause mortality during
hospital admission within 30-days of onset of CDAD. Data were
extractedbymedical microbiologists involved inpatient care orby a
member of the study team. Individuals who extracted data were not
aware of the ribotyping results. Data were double-entered,
compared and corrected using EpiData (v.3.1) software [16].
Analysis
We defined severe CDAD as having one or more of shock
(systolic BP 100 mmHg or less at any time, and/or oliguria),
paralytic ileus, pseudo membranous colitis or toxic megacolon. We
considered the following risk factors: infection with 027 or non-027
ribotypes, age group (by quintile), sex, previous discharge from any
hospital within 60 days prior to admission, having gastroenteritis
at admission, being immunocompromised, use of proton pump
inhibitors or H2 agonists within 8-weeks before diagnosis of
CDAD, use of antibiotics in the 8-weeks before diagnosis of
CDAD (where glycopeptides and metronidazole were considered
protective against CDAD and all other antibiotics were considered
as potential initiators of CDAD), and the hospital to which the
patient was admitted.
We conducted a single variable analysis wherein each risk factor
was examined for its association with severe CDAD. Variables
with probability p,0.3 in the single variable analysis were then
entered into a multivariable logistic regression model. The variable
for hospital was included as a random effect in the analysis; all
other variables were analysed as fixed effects. Analysis was done
using STATA 9.1 [17].
Ethical Approval
The study protocol was approved by the Cambridge Local
Research Ethics Committee (Ref: 06/Q0108/249).
Results
There were 136 patients admitted to a hospital in the East of
England with CDAD and from whom an isolate was included as
part of the national survey of C. difficile. We were able to obtain
clinical information for 123 patients (90%). There were slightly
fewer males than females (Table 1). The median age was 83 years
old, with a range of 3 to 98 years old and interquartile range of 75
to 89 years old (Table 1). The age distribution was skewed towards
the older ages (Figure 1). The most frequent diagnoses at
admission were gastrointestinal, respiratory, central nervous
system, urinary and renal complaints, cardiovascular and trauma
(Table 1). Twelve percent of patients (n=13/112) were immuno-
Table 1. Characteristics of patients with Clostridium difficile
associated disease, East of England, 2006
Patient Characteristics Number (%)
Demographic features [N=123]
Males 55 (44)
Median age in years (interquartile range) 83 (75 to 89)
Main diagnosis at admission [N=123] *
Gastrointestinal ** 26 (21)
Respiratory 20 (16)
Central Nervous System 19 (15)
Urinary & Renal 15 (12)
Cardiovascular 13 (11)
Trauma 12 (10)
Malignancy 9 (7)
Metabolic 4 (3)
Psychiatric 3 (2)
Skin 3 (2)
Muscular skeletal 3 (2)
Diabetes 3 (2)
Genital 0 -
Unspecified 16 (13)
Missing 5 (4)
Immunocompromised [N=112] {
Yes 13 (12)
No 99 (88)
Discharged from hospital prior to 60 days of current admission
[N=98] 1
Yes 44 (45)
No 54 (55)
PCR Ribotype 027 [N=123]
Yes 51 (41)
No 72 (59)
Severe Disease [N=123] {
Yes 24 (20)
No 99 (80)
30-day all cause mortality during hospital admission [117] 11
Yes 25 (21)
No 92 (79)
*Some patients had more than one diagnosis at admission
**3 patients were admitted with CDAD
{Data missing for 11 patients
{Severe CDAD defined as one or more of shock, paralytic ileus, pseudo
membranous colitis or toxic megacolon
1Data missing for 25 patients
11Data missing for 6 patients
doi:10.1371/journal.pone.0001812.t001
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charged from hospital within 60 days of the current admission
(Table 1). PCR ribotype 027 was identified in 41% (n=51/123)
of patients (Table 1). Severe disease was experienced by
20% (n=24/123) of patients (Table 1). A fifth (n=25/117) of
patients died (all causes) within 30-days of hospital admission
(Table 1).
Information about frequency of diarrhoea was recorded in the
medical records for 58 patients, of whom 78% (n=45) had 3–5
stools per day and 22% (n=13) has six or more stools per day.
Thirty four percent of patients (n=30/87) had abdominal pain,
while only 10% (n=8/78) had blood in the stool. Fever was
present in 13% (n=13/102) of patients. Leukocytosis was
recorded for 48% (n=52/108) of patients. Nineteen percent of
patients had shock (n=21/112), 3.7% (n=4/107) had paralytic
ileus, 4% (n=4/100) pseudomembranous colitis and one patient
had toxic megacolon.
In the eight weeks before onset of CDAD, 86% of patients had
been prescribed an antibiotic, with cephalosporins and quinolones
most frequently used, followed by penicillins, metronidazole and
macrolides (Table 2). Only 2% had been prescribed an antibiotic
protective against CDAD, while 51% had received other classes of
antibiotic (Table 2). Both initiating and protective antibiotics were
prescribed to 33% of patients. The number of classes of initiating
antibiotics taken in the eight weeks prior to onset of CDAD was
zero in 16% of patients, one in 20%, two in 31%, three in 15%
and four or more in 18% (Table 2). Proton pump inhibitors were
prescribed to about a third of patients while only 9% received an
H2 antagonist (Table 2).
Table 3 shows the proportion of patients with non-severe and
severe CDAD by C.difficile PCR ribotype. Of patients with
ribotype 027, 24% had severe CDAD compared to 17% of
patients with non-027 ribotypes. The 95% confidence intervals
(CI) for these two groups overlapped and included both point
estimates, indicating that they were not statistically different.
Results from the single variable analysis are shown in Table 4 and
ribotype 027, sex, discharge from hospital within 60 days of
current admission, gastroenteritis on admission, number of
initiator antibiotics for CDAD, and hospital where the patient
was admitted were included in the model. The result of the
multivariable model for CDAD severity is shown in Table 5. Only
sex showed a statistically significant association, with females less
likely to have severe disease compared to males.
Discussion
We did not find evidence to suggest that patients infected with
C. difficile PCR ribotype 027 were more likely to have severe
disease than patients infected with other PCR ribotypes. In a
multivariable model, men were more likely to have severe disease
than women. The number of antibiotics prescribed in the 8-weeks
prior to diagnosis of CDAD was not associated with greater disease
severity.
Strengths and Limitations
Selection bias in our patient sample was minimised as
recruitment was done without reference to ribotype or disease
severity. Patients for whom we could not obtain medical records
(10%) were more likely to have died. However, the proportion
with ribotype 027 was similar to patients included in our study and
is unlikely to have seriously biased our results. We reduced bias in
the measurement of CDAD severity by ensuring that individuals
who extracted clinical data had no prior knowledge of PCR
ribotype.
No standard definition for severe CDAD exists, although several
have been proposed [1,18]. To minimise misclassification bias we
used a conservative definition for categorising patients as severe
and less severe. Retrospective extraction of data from medical
records led to some missing data in this study, especially for
frequency of diarrhoea. Nevertheless, reviewing medical records is
likely to provide a more accurate picture of existing medical
practice than data collected during prospective studies.
Interpretation of Results
Our study provides a snapshot of patients with CDAD in
hospitals in the East of England region in 2006. While this patient
group predominantly consisted of the elderly, a notable proportion
(11%) of patients were under 65 years old, highlighting that
CDAD can occur in all age groups. High antibiotic ingestion (84%
of our patients had received at least one antibiotic in the 8-weeks
prior to onset of CDAD) is a cause for concern, given that
development of CDAD is recognised to generally follow exposure
to antibiotics. This reiterates the need for concerted efforts to limit
exposure to unnecessary antibiotics. We found that a higher
proportion of men had severe CDAD, possibly because they had
more severe underlying illness on admission to hospital, although
we were unable to consider this in our analysis. We also observed
Figure 1. Age of patients with Clostridium difficile associated disease, East of England, 2006
doi:10.1371/journal.pone.0001812.g001
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ribotype 027 compared to about 25% of CDAD patients in
England as a whole [14]. This may be due to geographical
clustering resulting from colonisation of hospitals with specific
strains [19]. Thirty day all cause mortality during hospital
admission was 21% in our study, which is similar to other studies
that report mortality rates ranging from 11% to 25%
[19,20,21,22].
Few studies have considered whether specific strains of C. difficile
cause more severe disease. Loo et al conducted a prospective study
of an outbreak of C. difficile in 12 hospitals in Quebec, Canada
[22]. Severe CDAD (defined as a patient who died within 30 days
of CDAD diagnosis and where C. difficile contributed to death, if
the patient had a colectomy or required admission to the intensive
care unit because of CDAD) occurred in 16.7% (n=22/132) of
patients with isolates that had both binary toxin and a partial
deletion in the tcdC gene (which represses production of toxin A
and toxin B). In a larger prospective study of 88 Quebec hospitals,
Hubert et al found that among 469 patients, severe CDAD (defined
as by Loo et al) was higher among patients infected with strains that
had both binary toxin and partial tcdC deletion [OR=2.1, 95%CI
0.98 to 4.6, p=0.054; adjusted for age] [19]. In France, Barbut et
al conducted a four-year retrospective study and found that among
137 patients, the risk of severe CDAD was higher among patients
with binary toxin positive strains [RR=3.3, 95%CI 1.29 to 8.85,
p=0.01], where severe CDAD was defined as presence of fever,
abdominal pain and leukocytosis; or endoscopically or histologi-
cally proven pseudomembranous colitis; or toxic megacolon,
perforation, colectomy, septic shock or death with C. difficile as the
primary or contributing factor [20]. In the Netherlands, Goorhuis
et al compared CDAD patients, of whom 218 had ribotype 027
and 645 had other ribotypes, between February 2005 and
November 2006 [23]. Patients with ribotype 027 had more severe
diarrhoea (OR=1.99, 95%CI 0.83 to 4.73), higher attributable
mortality (OR=3.30, 95%CI 0.41 to 26.4) and more recurrences
(OR=1.44, 95%CI 0.94 to 2.20), although the authors considered
these findings could be explained by bias in the selection of
patients and the low response rate (27%) in their study.
Our study had statistical power of 80% to detect a difference of
about 20% or greater at the 5% significance level in disease
severity among patients with PCR ribotype 027 compared to other
strains. To attribute the increasing incidence of C. difficile England
and other industrialised countries to a more virulent 027 strain, we
would expect it to cause severe disease in at least 20% or more of
patients. That we were unable to detect such a difference in
severity of CDAD in the 027 versus other ribotypes raises the
question of whether this strain can explain recent changes in the
epidemiology of C. difficile infection. Alternative explanations may
include greater risk of transmission of toxigenic strains within
health care facilities associated with sub-optimal hygiene [24],
greater patient susceptibility associated with prolific use of
antibiotics, and an increasingly elderly or vulnerable patient
population [25,26]. It is also likely that some of the reported
increase is due to surveillance artefact, reflecting more sensitive
and specific tests for C. difficile toxins A and B and more complete
reporting of cases.
Conclusions
We did not find evidence to suggest that patients infected with
C. difficile PCR ribotype 027 were more likely to have severe
Table 2. Treatment history for patients with Clostridium
difficile associated disease, East of England, 2006
Treatment History N %
Antibiotics used 8 weeks before CDAD* [N=123]
Any antibiotic 106 (86)
Cephalosporins 57 (46)
Quinolones 53 (43)
Penicillins 47 (38)
Metronidazole 38 (31)
Macrolides 23 (19)
Trimethroprim 17 (14)
Glycopeptides 10 (8)
Carbapenems 6 (5)
Aminoglycosides 2 (2)
Nitrofurantoin 1 (1)
Protective and Initiating antibiotics used in 8 weeks before CDAD **
[N=123]
Protective 3 (2)
Initiating 63 (51)
Both 40 (33)
None 17 (14)
Number of Initiating antibiotics used in 8 weeks before CDAD **
[N=123]
0 20 (16)
1 24 (20)
2 38 (31)
3 19 (15)
41 0 ( 8 )
51 1 ( 9 )
6 1 (1)
Proton pump inhibitors [N=109] {
Yes 42 (39)
No 67 (61)
H2 antagonists [N=89] {
Yes 7 (9)
No 82 (92)
*Some patients were prescribed antibiotics from more than one class
**Protective antibiotics: glycopeptides and metronidazole
{Data missing for 14 patients
{Percentages do not sum to 100% due to rounding. Data missing for 34
patients
doi:10.1371/journal.pone.0001812.t002
Table 3. Proportion of patients with severe Clostridium
difficile associated disease and deaths during admission (all
causes) by PCR ribotype 027
Severity of Clostridium difficile associated disease
Number of patients % Severe 95% CI
PCR
ribotype
027
Non-
severe Severe Total
Y e s3 91 25 12 41 3 t o 3 7
No 60 12 72 17 9 to 27
Total 99 24 123 20 13 to 28
doi:10.1371/journal.pone.0001812.t003
Clinical Severity of C.diff
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1812Table 4. Single variable analysis of risk factors for severe Clostridium difficile associated disease (CDAD), East of England, 2006
Clinical Severity
Severe Not Severe Odds Ratio 95%CI P-value
Sex Male 14 41 0.14*
[N=123] Female 10 58 0.50 0.20 to 1.25
Age group (years) 3–68 6 18 0.9
[N=123] 69–79 5 18 0.83 0.22 to 3.23
80–84 4 19 0.63 0.15 to 2.61
85–89 4 20 0.60 0.15 to 2.47
90–98 5 24 0.63 0.16 to 2.37
Discharged from hospital prior to 60
days of current admission
No 8 46 0.21*
[N=98] Yes 11 33 1.92 0.69 to 5.29
Immunocompromised No 16 83 0.9
[N=112] Yes 11 2 0.94 0.19 to 4.67
PCR ribotype 027 No 12 60 0.3
[N=123] Yes 12 39 1.54 0.63 to 3.77
Proton pump inhibitors or H2 antagonists
used in 8-weeks before CDAD
No 12 51 0.9
[N=109] Yes 9 37 1.04 0.39 to 2.71
Gastroenteritis on admission No 16 81 0.12*
[N=123] Yes 8 18 2.25 0.84 to 6.06
Protective and inciting antibiotics used
in 8-weeks before CDAD
Protective 1 2 0.8
[N=106] Inducing 15 48 0.63 0.05 to 7.39
Both 8 32 0.5 0.04 to 6.23
Number of initiator antibiotics used
in 8-weeks before CDAD
0 1 19 0.22*
[N=123] 1 6 18 6.33 0.69 to 57.9
2 9 29 5.9 0.69 to 50.4
3+ 8 33 4.61 0.53 to 39.7
Hospital Trust [N=123] Proportion of total variance contributed by
Trust variance
0.16 0.03 to 0.53 0.034*
*Included in the multivariable model
doi:10.1371/journal.pone.0001812.t004
Table 5. Multivariable logistic regression model of risk factors for severe Clostridium difficile associated disease (CDAD), East of
England, 2006
Risk Factor Odds Ratio 95% CI p-value
PCR ribotype 027 No 1.00
Yes 2.07 0.63 to 6.81 0.23
Sex Male 1.00
Female 0.26 0.08 to 0.89 0.03
Discharged from hospital prior to 60 days of
current admission
No 1.00
Yes 1.92 0.56 to 6.61 0.3
Gastroenteritis admission No 1.00
Yes 1.40 0.31 to 6.3 0.7
Number of initiator antibiotics before CDAD 0 0.8
1 2.64 0.2 to 34.3
2 3.31 0.29 to 38.1
3+ 2.14 0.17 to 26.5
Hospital Proportion of total variance
contributed by trust variance
0.13 0.01 to 0.73 0.18
doi:10.1371/journal.pone.0001812.t005
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finding does not support claims that the emergence of ribotype 027
infections can explain reported increases in incidence of C. difficile
infections in England. Our results may have relevance to other
countries in which virulence associated with the emergence of the
027 ribotype has also been suggested as an explanation for
increased incidence of C. difficile infections.
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